MDxHealth has signed an agreement with PLUS Diagnostics to co-promote its ConfirmMDx for prostate cancer in the US.
ConfirmMDx is a laboratory-developed test (LDT), which assists urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and helps rule in high risk patients who may require repeat biopsies and potential treatment.
The prostate cancer test can also detect a proven epigenetic field effect or halo associated with the cancerization process at the DNA level in cells adjacent to cancer foci.
PLUS Diagnostics CEO David Pauluzzi said, "We believe this test will improve the standard of care for patients with negative prostate biopsies."
The company intends to launch ConfirmMDx for prostate cancer in Q2, 2012.
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.